Shinichiro Migoh

Kyushu University, Hukuoka, Fukuoka, Japan

Are you Shinichiro Migoh?

Claim your profile

Publications (6)6.72 Total impact

  • Shinichiro Migoh · Keitaro Hasuda · Kimihiro Nakashima · Hideaki Anai ·
    [Show abstract] [Hide abstract]
    ABSTRACT: Laparoscopy-assisted distal gastrectomy is a surgical procedure which is safe, useful, and technically feasible for patients with early gastric cancer. The aim of this study is to determine whether laparoscopy-assisted distal gastrectomy is also superior to conventional open distal gastrectomy. The study comprised 27 consecutive patients with early gastric cancer who were admitted to our hospital from 1997 to 2000 and underwent distal gastrectomy. Ten patients underwent laparoscopy-assisted distal gastrectomy; and 17 conventional open distal gastrectomy. Estimated blood loss was 17.7 +/- 12.1 g during laparoscopy-assisted distal gastrectomy, and 250.0 +/- 160.8 g during conventional open distal gastrectomy. The difference was statistically significant (p < 0.001). The day of ambulation (2.7 +/- 0.7 vs. 1.0 +/- 0.0), and start of liquid diet (6.9 +/- 1.2 vs. 4.3 +/- 0.5) were significantly delayed in conventional open distal gastrectomy compared with laparoscopy-assisted distal gastrectomy (p < 0.001, p < 0.05). At the 3rd postoperative day, the serum C-reactive protein level in laparoscopy-assisted distal gastrectomy decreased significantly more than that in conventional open distal gastrectomy (4.2 +/- 1.7 vs. 9.4 +/- 2.5: p < 0.05). No postoperative complication was found in laparaoscopy-assisted distal gastrectomy. Laparoscopy-assisted distal gastrectomy is a safe and useful operation for most early gastric cancers. Laparoscopy-assisted distal gastrectomy has been superior to conventional open distal gastrectomy.
    Hepato-gastroenterology 11/2003; 50(54):2251-4. · 0.93 Impact Factor
  • Yoshitake Ueda · Kimihiro Nakashima · Shinichiro Migoh · Hideaki Anai ·

    Journal of Microwave Surgery 01/2001; 19:77-80. DOI:10.3380/jmicrowavesurg.19.77
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to determine the role of endothelin (ET)-1 in portal hypertensive gastropathy (PHG) under portal hypertension, in order to investigate whether the ET(A/B) receptor inhibitor improves the permeability of gastric mucosal microvessels in PHG. Portal hypertensive rats (PVL) and sham-operated rats (CTR) were prepared and then the concentration of plasma ET-1 was measured and the vasopressor response to ET-1 was compared between the two groups. The plasma ET-1 levels in PVL increased significantly compared with CTR; however, the vasopressor response to ET-1 in PVL decreased more than in CTR. Next, the portal venous pressure was measured in both CTR and PVL pretreated with or without a nitric oxide (NO) synthase inhibitor, N(G)-nitro-L-arginine methyl ester (L-NAME), before the injection of ET-1. The portal venous pressure of PVL after receiving ET-1 and being pretreated with L-NAME significantly increased in comparison to the pressure of PVL treated with ET-1 alone (without L-NAME). Moreover, Evans-Blue was injected into each rat and the absorbancy of the gastric contents was measured. The absorbancy of Evans-Blue in PVL increased significantly compared with CTR; however, the absorbancy in PVL+ ET(A/B) receptor inhibitor (Ro47-0203) decreased significantly more than in PVL. This study showed that ET-1 is a potent vasoconstrictive substance that also has a transitory vasodilative response through NO induced by ET-1 in portal hypertension. In addition, it was found that the vascular permeability of the gastric mucosa increased in portal hypertension and that Ro47-0203 inhibited the hyper-permeability. Accordingly, ET-1 may, thus, play an important role in the development of PHG through NO induced by ET-1. Ro47-0203 may, therefore, be a useful substance for improving PHG in portal hypertension.
    Journal of Gastroenterology and Hepatology 03/2000; 15(2):142-7. DOI:10.1046/j.1440-1746.2000.02061.x · 3.50 Impact Factor
  • Shinichiro Migoh · Kimihiro Nakashima · Hideaki Anai ·

    Journal of Microwave Surgery 01/2000; 18:133-136. DOI:10.3380/jmicrowavesurg.18.133
  • Shinichiro Migoh · Keitaro Hasuda · Takeshi Oka · Kimihiro Nakashima · Hideaki Anai ·

    Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 01/2000; 61(7):1750-1754. DOI:10.3919/jjsa.61.1750
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Laparoscopic splenectomy has been demonstrated to be technically feasible and safe for the treatment of immune thrombocytopenic purpura (ITP), hereditary spherocytosis, and Hodgkin's disease. The study comprised 76 consecutive patients with chronic ITP who were admitted to our hospital from 1968 to 1997 and underwent splenectomy; 35 patients underwent a laparoscopic splenectomy, and 41 had open surgery. Laparoscopic splenectomy involved minimal incision, and a significantly lower frequency of analgesia was required for postoperative abdominal pain (1.4 versus 3.3); postoperative hospital stay was shorter (9.6 versus 20.1 days, P <0.05). Operative time was significantly longer for the laparoscopic surgery (204.5 versus 99.8 minutes, P <0.01), but blood loss was less (154.4 versus 511.7 g, P <0.01). During the present study (range 3.8 to 80 months), accumulative nonrecurrence rate was 67.9% in 5 years after surgery, which is similar to that of the previous open splenectomy. Laparoscopic splenectomy can become an alternative therapeutic modality in the treatment of ITP.
    The American Journal of Surgery 04/1999; 177(3):222-6. DOI:10.1016/S0002-9610(99)00014-8 · 2.29 Impact Factor